{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:26:53Z","timestamp":1793820413653,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011338","name":"AstraZeneca AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.102041","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T17:24:24Z","timestamp":1697477064000},"page":"102041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study"],"prefix":"10.1016","volume":"8","author":[{"given":"S.","family":"Joris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rasschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"T\u2019Kint de Roodenbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Decoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De Gr\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2023.102041_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102041_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100524","article-title":"PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment","volume":"7","author":"Thouvenin","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102041_bib3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.21873\/anticanres.16348","article-title":"Somatic variants in DNA damage response genes in ovarian cancer patients using whole-exome sequencing","volume":"43","author":"Lopacinska-Joergensen","year":"2023","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102041_bib4","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.3390\/ijms23094709","article-title":"Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients","volume":"23","author":"Dalmasso","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2023.102041_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102041_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2019-0689","article-title":"Olaparib for advanced breast cancer","volume":"16","author":"Griguolo","year":"2020","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102041_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2023.102041_bib8","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.3390\/cancers14235922","article-title":"Clinical application of poly(ADP-ribose) polymerase (PARP) inhibitors in prostate cancer","volume":"14","author":"Inderjeeth","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102041_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"44","key":"10.1016\/j.esmoop.2023.102041_bib10","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102041_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/cge.12620","article-title":"Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients","volume":"89","author":"De Brakeleer","year":"2016","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102041_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102041_bib13","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMc1810168","article-title":"Olaparib desensitization in a patient with recurrent peritoneal cancer","volume":"379","author":"Grabowski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102041_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102041_bib15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2023.102041_bib16","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2023.102041_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102041_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14740338.2022.2047176","article-title":"An update on the safety of olaparib for treating ovarian cancer","volume":"21","author":"Cottrell","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102041_bib20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102041_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.102041_bib22","article-title":"Case report: olaparib shows satisfactory clinical outcomes against small cell esophageal carcinoma with ATM mutation","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102041_bib23","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"43","author":"Bakr","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102041_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/BST20220681","article-title":"Targeting the DNA damage response for cancer therapy","volume":"51","author":"Curtin","year":"2023","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102041_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12885-023-10772-y","article-title":"ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors","volume":"23","author":"Parvin","year":"2023","journal-title":"BMC Cancer"},{"issue":"36","key":"10.1016\/j.esmoop.2023.102041_bib26","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of\u00a0olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102041_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102041_bib28","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","article-title":"Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD","volume":"32","author":"Hodgson","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102041_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonzalez-Martin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102041_bib30","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3390\/cancers14102453","article-title":"BRCA-mutated pancreatic cancer: from discovery to novel treatment paradigms","volume":"14","author":"Devico Marciano","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102041_bib31","doi-asserted-by":"crossref","first-page":"NP30","DOI":"10.1177\/03008916221132589","article-title":"Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: what could we expect?","volume":"108","author":"Garajova","year":"2022","journal-title":"Tumori"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102041_bib32","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1245\/s10434-022-11917-2","article-title":"A\u00a0randomized study of olaparib or placebo in patients with surgically removed pancreatic cancer who have a BRCA1, BRCA2 or PALB2 mutation (the APOLLO trial)","volume":"29","author":"Teke","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102041_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102041_bib34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/jnci\/djz012","article-title":"RE: BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis","volume":"111","author":"Katona","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2023.102041_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102923","article-title":"Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity","volume":"59","author":"Smeby","year":"2020","journal-title":"EBioMedicine"},{"issue":"48","key":"10.1016\/j.esmoop.2023.102041_bib36","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.3748\/wjg.v22.i48.10680","article-title":"Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein","volume":"22","author":"Ghiringhelli","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102041_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101198","article-title":"Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer","volume":"8","author":"Martini","year":"2023","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102041_bib38","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102041_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.997009","article-title":"Treatment and outcome of metastatic parathyroid carcinoma: a systematic review and pooled analysis of published cases","volume":"12","author":"Alberti","year":"2022","journal-title":"Front Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:23Z","timestamp":1761856223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923012826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923012826"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102041","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102041"}}